Sotabase

Career

· Fellow, University of Wisconsin-Madison Center for High Throughput Computing (CHTC)2024–
· Business Executive / Product & Engineering Leader, Care.com International
· Business Executive / Product & Engineering Leader, HomePay
· Scaled Product & Engineering orgs, SoundCloud
· Scaled Product & Engineering orgs, Vimeo

Publications (13)

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
The Pediatric Infectious Disease Journal · 1996
88
cited
Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization.
Journal of Infectious Diseases · 1995
68
cited
Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
The Pediatric Infectious Disease Journal · 1996
67
cited
Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
Clinical Infectious Diseases · 1997
66
cited
Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults
1995
66
cited
Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children
The Pediatric Infectious Disease Journal · 2002
59
cited
Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers.
Vaccine · 1998
52
cited
Safety and Immunogenicity of a Combined Live Attenuated Measles, Mumps, Rubella, and Varicella Vaccine (MMRIIV) in Healthy Children
1996
46
cited
Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX.
The Pediatric Infectious Disease Journal · 1998
27
cited
Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Journal of Infectious Diseases · 1996
21
cited
Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group.
Vaccine · 1995
15
cited
Low incidence of adverse experiences after measles or measles-rubella mass revaccination at a college campus.
Vaccine · 1994
6
cited
SAFETY AND IMMUNOGENICITY OF CONCOMITANT SEPARATE ADMINISTRATION OF MMRII, TETRAMUNE (WYETH LEDERLE DPT & HbOC) AND VARIVAX (OKA/MERCK VARICELLA VACCINE) VS. CONCOMITANT INJECTIONS OF MMRII AND TETRAMUNE• 660
Pediatric Research · 1996
Sotabase